Skip to content

IACH MPNCo&D 2023 GSK symposium evaluation form

Raising the Bar in Cytopenic Myelofibrosis

This information is intended for healthcare professionals only. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.
NX-GBL-MML-QST-230002 September 2023
1.Which describe(s) your qualifications (check all that apply)?
2.Which describe(s) your credentials (check all that apply)?
3.Please check the box that indicates the number of patients with myelofibrosis in your practice.
4.Please evaluate whether the objectives of this symposium were met.
Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
Outline the implications and medical needs associated with anaemia and thrombocytopenia in patients with myelofibrosis
Provide an overview of available and emerging agents in patients with myelofibrosis, with a focus on patients with myelofibrosis who have anaemia and/or thrombocytopenia
Review patient cases and discuss clinical decision-making with current and upcoming treatment options for patients with myelofibrosis who have anaemia and/or thrombocytopenia
5.As a result of attending this symposium, I am confident I will improve my knowledge, competence, performance, and/or patient outcomes.
Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
6.What would you like to learn more about at future meetings (check all that apply)?